Adagene (ADAG) announced data at the SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. The two poster presentations ...

PhD LBA72 - Nivolumab 3mg/kg and Ipilimumab 1mg/kg (Nivo3/ipi1) in Molecularly Selected Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1599P - Symptomatic Skeletal Events, ...

In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received pembrolizumab developed immune-related adverse events — findings that ...

CHICAGO — In patients with stage IVB anaplastic thyroid cancer, the inclusion of adjuvant pembrolizumab to conventional multimodal therapy shows significant benefits in reducing the recurrence ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Dr. Shannon Westin (Host), Dr. Brian Slomovitz (Guest) Dr. Shannon Westin and her guest, Dr. Brian Slomovitz discuss the article “Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved two new indications for KEYTRUDA ® (pembrolizumab), Merck ...

At a median follow-up of 29.9 months (range, 12.8-43.0), significant differences in overall survival (OS) were observed between the pembrolizumab plus chemoradiotherapy group and the chemoradiotherapy ...

Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer. Ivonescimab reduced the risk of ...

Your browser does not support the audio element. MG Motor has released the first set of images and details of an all-new ES5 electric SUV. The ES5 will be a global ...